All In Biotech

Drug Trial Radar · NCT00151749

WelChol® and Insulin in Treating Patients With Type 2 Diabetes

A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of the Efficacy and Safety of WelChol® in Type 2 Diabetes With Inadequate Glycemic Control on Insulin Therapy Alone or Insulin Therapy Combination With Other Oral Anti-diabetic Agents

Last checked: Nov 19, 2026Latest source record: Jan 18, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 260 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

260

Actual

Start

Jun 2004

Primary completion

Dec 2005

Study completion Dec 2005

Sponsor

Lead sponsor
Daiichi SankyoDaiichi Sankyo (DSNKY)
Sponsor type
Industry
First posted
Sep 9, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to see how safe and effective and tolerable the use of WelChol® is for type 2 diabetes when added to insulin alone or in combination with other anti-diabetic drugs

Conditions

  • Type 2 Diabetes

Interventions

  • Colesevelam hydrochlorideDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. - To assess the additional lowering of HbA1c achieved by
  2. addition of WelChol® to current antidiabetic therapy

Locations

47 sites in 3 countries. Site status is shown where the registry gives one.

  • Site not named

    Tuscumbia, Alabama

  • Site not named

    Sierra Vista, Arizona

  • Site not named

    Jonesboro, Arkansas

  • Site not named

    Searcy, Arkansas

  • Site not named

    Carmichael, California

  • Site not named

    Concord, California

  • Site not named

    Fullerton, California

  • Site not named

    La Jolla, California

  • Site not named

    San Diego, California

  • Site not named

    West Hills, California

  • Site not named

    Washington D.C., District of Columbia

  • Site not named

    Largo, Florida

  • Site not named

    Miami, Florida

  • Site not named

    New Port Richey, Florida

  • Site not named

    West Palm Beach, Florida

  • Site not named

    Chicago, Illinois

  • Site not named

    Indianapolis, Indiana

  • Site not named

    Lexington, Kentucky

  • Site not named

    Louisville, Kentucky

  • Site not named

    New Orleans, Louisiana

  • Site not named

    Boston, Massachusetts

  • Site not named

    Troy, Michigan

  • Site not named

    Edina, Minnesota

  • Site not named

    Chesterfield, Missouri

  • Site not named

    Kansas City, Missouri

  • Site not named

    St Louis, Missouri

  • Site not named

    Bozeman, Montana

  • Site not named

    Butte, Montana

  • Site not named

    Englewood, New Jersey

  • Site not named

    Charlotte, North Carolina

  • Site not named

    Hickory, North Carolina

  • Site not named

    Raleigh, North Carolina

  • Site not named

    Statesville, North Carolina

  • Site not named

    Winston-Salem, North Carolina

  • Site not named

    Cincinnati, Ohio

  • Site not named

    Marion, Ohio

  • Site not named

    Portland, Oregon

  • Site not named

    Beaver, Pennsylvania

  • Site not named

    Charleston, South Carolina

  • Site not named

    Bristol, Tennessee

Showing 40 of 47 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.